AUS
NZ
UK
CA
USA
IND
Highlights
Cleo integrates advanced diagnostic platform.
Automated technology supports early cancer detection.
Regulatory pathway and supply discussions progress.
Cleo Diagnostics adopts an advanced automated testing platform to enhance ovarian cancer detection, strengthen clinical validation, and advance regulatory progress, supporting broader diagnostic adoption across global healthcare laboratories.
Cleo Diagnostics Selects Next-Generation Ella Platform to Deliver Ovarian Cancer Blood Test marks a significant step in diagnostic innovation, as Cleo Diagnostics (ASX:COV) moves closer to commercialising its ovarian cancer detection technology. The company has chosen the advanced Ella automated enzyme-linked immunosorbent assay platform developed by Bio-Techne Corporation to support its proprietary testing process.
The decision reflects continued innovation within the broader Australian Securities Exchange ecosystem, where healthcare technology companies continue to shape developments across the ASX stock market. The adoption of automated diagnostics aims to improve detection accuracy, streamline laboratory processes, and support early identification of ovarian cancer through a simple blood-based approach.
Technology Integration Supports Diagnostic Innovation
Advanced Platform Selection
Cleo Diagnostics has selected the Ella platform to process patient blood samples using highly automated laboratory methods. The system is designed to generate accurate and reproducible results while reducing manual intervention, enabling laboratories to conduct complex analyses efficiently.
The platform introduces improved assay sensitivity and precision, helping clinicians identify disease-related biomarkers with greater clarity. Unlike traditional testing systems, Ella can simultaneously analyse multiple biomarkers, allowing broader diagnostic insights from a single blood sample.
Microfluidic cartridge technology plays a central role in the process. These cartridges measure Cleo’s proprietary biomarker panel, which provides key inputs for the algorithm behind its patented ovarian cancer testing technology. The integration of automation and precision analytics reflects a growing shift toward advanced diagnostic solutions in modern healthcare.
Improved Efficiency and Workflow
The automated platform simplifies laboratory workflows by reducing repetitive manual steps, supporting consistency in results across testing environments. This standardised process is expected to help diagnostic laboratories deliver timely assessments while maintaining high-quality outcomes.
The technology also enhances scalability, making the testing process suitable for widespread clinical use. Compatibility with existing laboratory equipment further supports adoption, enabling healthcare facilities worldwide to integrate the testing method without extensive infrastructure changes.
Platform Validation and Regulatory Progress
Confirmation of Performance
Cleo Diagnostics began working with the Ella platform during earlier testing phases and has confirmed its ability to deliver reliable results for ovarian cancer detection. The successful evaluation of the system supports its use in upcoming validation activities.
The company and Bio-Techne are progressing discussions toward a formal agreement to use the platform for analytical validation of Cleo’s testing kits. These activities represent a key milestone in demonstrating the reliability and effectiveness of the diagnostic solution.
Clinical Trial and Data Generation
As part of its clinical development pathway, Cleo Diagnostics plans to analyse several hundred patient blood samples collected during a pivotal clinical study. The results from this research will contribute to the data package required for submission to U.S. Food and Drug Administration under its regulatory review framework.
Regulatory progress is essential for introducing the test to global healthcare markets. The submission process will evaluate the test’s performance, accuracy, and clinical value, ensuring that it meets established safety and effectiveness standards.
Supply Agreement Discussions
Alongside validation efforts, Cleo Diagnostics and Bio-Techne are preparing to establish a long-term commercial supply arrangement. The agreement would support manufacturing and distribution of testing kits once regulatory activities are completed.
This collaboration highlights the importance of strategic partnerships in advancing healthcare technology, enabling companies to combine expertise in diagnostics, manufacturing, and clinical research.
Early and Accurate Detection of Ovarian Cancer
Focus on Early Diagnosis
Cleo Diagnostics is developing a blood-based test designed to support accurate and early detection of ovarian cancer. Early diagnosis remains a critical challenge in oncology, as symptoms often appear at later stages of the disease.
The company’s approach centres on a patented biomarker known as CXCL ten, which is produced at elevated levels during the early development of ovarian cancer but remains largely absent in benign conditions. Detecting this biomarker enables clinicians to distinguish between non-cancerous and malignant growths more effectively.
Addressing Diagnostic Challenges
Traditional diagnostic pathways often rely on multiple clinical assessments, including imaging techniques and standard biomarker testing. These methods may not always provide clear differentiation between benign and malignant conditions, creating uncertainty in clinical decision-making.
Cleo’s technology aims to simplify this process by offering a standardised blood test capable of delivering reliable insights. The test is designed to integrate seamlessly into existing diagnostic workflows, supporting widespread clinical adoption.
Clinical Research Foundation
The technology is supported by extensive scientific research conducted at the Hudson Institute of Medical Research in Victoria. Years of development have contributed to the understanding of ovarian cancer biomarkers and their clinical applications.
Clinical studies involving hundreds of patients have evaluated the effectiveness of the test, demonstrating its ability to detect early-stage disease more effectively than conventional diagnostic approaches. These findings highlight the potential impact of advanced biomarker-based testing in improving patient outcomes.
Impact on Healthcare and Medical Diagnostics
Transforming Patient Care
The development of accurate and accessible diagnostic tools can significantly influence patient care pathways. Earlier identification of ovarian cancer allows healthcare professionals to initiate appropriate treatment strategies sooner, potentially improving clinical outcomes and survival rates.
Automated testing platforms such as Ella also support consistent performance across laboratories, helping ensure that patients receive reliable results regardless of location.
Global Laboratory Compatibility
The test’s design enables compatibility with widely used laboratory equipment, supporting adoption across diverse healthcare systems. This adaptability strengthens the possibility of global implementation, making advanced diagnostics accessible to a broader patient population.
As healthcare providers increasingly adopt precision medicine approaches, technologies that enable accurate biomarker analysis are expected to play a central role in disease management.
Innovation Within the Australian Market
Healthcare innovation continues to emerge as a dynamic segment within the Australian financial landscape. Companies advancing medical technology contribute to broader developments across market indices such as the ASX 100 and the ASX 200, reflecting the growing influence of biotechnology and diagnostic research.
While sectors such as ASX mining stocks and ASX dividend stocks often dominate market discussions, healthcare innovation continues to attract attention for its long-term societal impact. Companies involved in diagnostic technologies contribute to diversification across indices including the ASX 300.
Future Outlook for Cleo Diagnostics
Expanding Diagnostic Capabilities
The integration of advanced automation and biomarker analysis represents a major step in Cleo Diagnostics’ development journey. Continued research and validation activities are expected to strengthen the clinical value of its ovarian cancer test.
Future developments may include expanded applications of the technology and further refinement of diagnostic algorithms, supporting broader use across healthcare settings.
Strengthening Industry Partnerships
Collaboration with Bio-Techne highlights the importance of partnerships in advancing medical innovation. Combining expertise in biomarker research, automated testing platforms, and clinical validation supports the development of reliable diagnostic solutions.
As regulatory and commercial milestones are achieved, the collaboration may contribute to large-scale manufacturing and distribution of testing kits.
Supporting Global Healthcare Needs
Ovarian cancer remains a significant global health challenge. Technologies that enable early and accurate detection have the capacity to transform screening practices and improve patient outcomes.
Cleo Diagnostics’ progress reflects the growing role of biotechnology in addressing complex medical conditions through data-driven approaches and precision diagnostics.
Cleo Diagnostics’ adoption of the Ella automated platform represents a meaningful step forward in ovarian cancer detection technology. By combining advanced biomarker research, automated laboratory processes, and regulatory progress, the company continues to advance its diagnostic solution toward broader clinical use.
The initiative highlights the importance of innovation in medical technology and its potential to improve healthcare outcomes worldwide. As validation activities and regulatory steps progress, the development underscores the evolving role of biotechnology within modern healthcare systems and the broader Australian market landscape.
